Highly potent and selective chiral inhibitors of PDE5: An illustration of Pfeiffer’s rule
Authors:
- Mark E. BunnageMBMark E. Bunnage
- John P. MathiasJMJohn P. Mathias
- Anthony WoodAWAnthony Wood
- Duncan MillerDMDuncan Miller
- Stephen D.A. StreetSSStephen D.A. Street
- 1 December 2008
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 18 (23) , 6033-6036
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- The influence of drug-like concepts on decision-making in medicinal chemistryNature Reviews Drug Discovery, 2007
- Phosphodiesterase 5 (PDE 5) inhibitors for the treatment of male erectile disorder: Attaining selectivity versus PDE6Medicinal Research Reviews, 2005
- Phosphodiesterase 5 inhibitors: current status and potential applicationsNature Reviews Drug Discovery, 2002
- Molecular Complexity and Its Impact on the Probability of Finding Leads for Drug DiscoveryJournal of Chemical Information and Computer Sciences, 2001
- Potential role for P-glycoprotein in the nonproportional pharmacokinetics of UK-343,664 in manXenobiotica, 2001
- The role of phosphodiesterase inhibitors in impotenceExpert Opinion on Investigational Drugs, 1997
- Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settingsAdvanced Drug Delivery Reviews, 1997
- Sildenafil (VIAGRATM), a potent and selective inhibitor of type 5 cGMP phosphodiesterase with utility for the treatment of male erectile dysfunctionBioorganic & Medicinal Chemistry Letters, 1996
- Quantitative structure-activity relationships and eudismic analyses of the presynaptic dopaminergic activity and dopamine D2 and .sigma. receptor affinities of 3-(3-hydroxyphenyl)piperidines and octahydrobenzo[f]quinolinesJournal of Medicinal Chemistry, 1987
- Optical Isomerism and Pharmacological Action, a GeneralizationScience, 1956